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1875-9572/Copyrightª 2016, Taiwan P
NC-ND license (http://creativecommoBackground: Erythropoietin (EPO) administration prevents anemia of prematurity and may be
associated with a significant increase in the risk of retinopathy of prematurity (ROP) in preterm
infants. Nonetheless, early EPO treatment may prevent damage following retinal neovascular-
ization. The aim of this meta-analysis was to elucidate whether EPO administration increases
the risk of ROP.
Methods: We searched MEDLINE, PubMed, CINAHL (Cumulative Index to Nursing and Allied
Health Literature), and the Cochrane Central Register of Controlled Trials with no language re-
strictions. Randomized controlled trials that reported the association between EPO treatment
in preterm infants and ROP were eligible. All of the included studies were stratified into two
groups according to the age of initiation of EPO treatment: before 8 days of age (early EPO),
and 8e28 days of age (late EPO).
Results: Thirteen studies were identified that included a total of 1999 preterm infants. EPO
administration did not increase the risk of ROP of any stage or Stage 3 (any relative risk:
0.99, 95% confidence interval: 0.84e1.16, p Z 0.89; Stage 3 relative risk: 1.34, 95% confi-
dence interval: 0.90e1.99, p Z 0.15). This trend remained unchanged in both the early and
late EPO groups. There did not seem to be any evidence of publication bias for outcomes as
the funnel plots were symmetrical.of Pediatrics, China Medical University Hospital, 2 Yuh Der Road, Taichung 404, Taiwan.
.org.tw (H.-C. Lin).
hou H-H, et al., Early Erythropoietin Administration does not Increase the Risk of Retinopathy in
atology (2016), http://dx.doi.org/10.1016/j.pedneo.2016.03.006
016.03.006
ediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
ns.org/licenses/by-nc-nd/4.0/).
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Preterm Infants, Pediatrics and NeonConclusion: EPO administration did not significantly increase the risk of ROP of any stage re-
ported or Stage 3. Further clinical trials investigating the impact of EPO on ROP in premature
infants should include all confounding factors to clarify this important issue.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Several studies have shown that early erythropoietin (EPO)
administration is effective in the prevention of anemia and
reduces the need for red blood cell (RBC) transfusion in
preterm infants.1e3 Despite the beneficial effects of EPO in
preterm infants, a Cochrane review reported that although
there was no significant increase in the rate of Stage 3
retinopathy of prematurity (ROP) in studies that initiated
EPO treatment at <8 days of age.4 In post hoc analysis
including all studies regardless of age at initiation of treat-
ment therewas an increased risk of ROP in the EPO treatment
group. A recent retrospective study also showed that EPO
therapy appears to increase the risk of developing and
worsening of ROP.5 Due to the limited benefits and increased
risk of ROP, the early administration of EPO was not recom-
mended by several studies5,6 and the Cochrane review.4
ROP is characterized by peripheral retinal ischemia and
secondary neovascularization with neuro-vascular degen-
eration.7 Thus, one way to reduce the risk of blindness from
retinal neovascularization is to prevent the retinal vascul-
opathy that precedes and causes it. EPO has been reported
to be a powerful cytoprotective agent that protects both
neurons and vascular cells from apoptosis and mobilizes
bone marrow progenitor cells to the peripheral blood
stream for vascular repair.8e10 EPO was also shown to pro-
tect developing retinas in an ovine model of endotoxin-
induced retinal injury.11 In addition, the short-term sys-
temic administration of exogenous EPO in the early stages
of retinal ischemia was found to improve retinal neuronal
function, prevent retinal capillary dropout, and subsequent
neovascularization in an animal model of oxygen-induced
retinopathy.9,10
A recent retrospective analysis of 718 very low birth
weight infants showed that early use of EPO did not lead to
an increased risk of severe ROP (only Stage 1).12 The au-
thors speculated that the increase in Stage 3 ROP observed
in other studies may be due to the concomitant actions of
EPO and high doses of iron.
Furthermore, EPO has been shown to have beneficial
neurological effects in recent animal studies, including
decreases in hemorrhagic volume, hypoxic-ischemic brain
injury, neuronal apoptosis, and neurological deteriora-
tion.13,14 High-dose EPO treatment has been associated
with a modest improvement in neurodevelopmental out-
comes,15 and a reduced risk of brain injury on magnetic
resonance imaging at a term-equivalent age.16
Given the controversial effects of EPO in preterm in-
fants, there is an urgent need to clarify the impact of EPO
on ROP before further prospective control trials are con-
ducted to investigate the neuroprotective effects of EPO inhou H-H, et al., Early Erythropo
atology (2016), http://dx.doi.orgthese vulnerable preterm infants. Therefore, we conducted
this updated meta-analysis of currently available random-
ized controlled trials (RCTs) and quasi-RCTs to assess the
effectiveness and safety of the early initiation of EPO in
reducing ROP in preterm and/or low birth weight infants.
2. Methods
2.1. Inclusion criteria
RCTs or quasi-RCTs (i.e., those with an inadequate alloca-
tion concealment),17 which recruited preterm neonates
with a gestational age of <37 weeks and/or birth weight
<2500 g were included in this meta-analysis. These in-
terventions assessed the effects of EPO versus a placebo or
no treatment on ROP.
2.2. Search strategy
MEDLINE (1966 to August 2014), PubMed (1966 to August
2014), and CINAHL (Cumulative Index to Nursing and Allied
Health Literature; 1982 to August 2014) databases were
searched to identify RCTs. The Cochrane Central Register of
Controlled Trials (CENTRAL) was also searched. The
following medical subject heading terms and text words
were used: (erythropoietin OR epoetin OR rhuepo OR EPO)
AND (retinopathy of prematurity OR ROP) AND (low birth
weight OR prematurity OR preterm). We restricted the
search to human studies, and no language restrictions were
applied. Additional information was retrieved via a manual
search of references from recent reviews and relevant
published original studies.
2.3. Data extraction
Two reviewers (Chou and Lin) independently reviewed each
reference identified through the search, scanned the full
texts of the relevant studies, applied the inclusion criteria,
and extracted data separately on a data abstraction form.
The extracted data included baseline characteristics of the
included trials, the study drugs, doses, use of a placebo or
no treatment, follow up, and loss of follow up. The primary
outcome of interest was the number of patients who
developed ROP (including ROP of any stage reported and
Stage 3). One review author (Chou) entered data into
Review Manager (RevMan) version 5.0 statistical software
(Cochrane Collaboration, Oxford, UK), and the other (Lin)
cross-checked the printout against his own data abstraction
forms.ietin Administration does not Increase the Risk of Retinopathy in
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We performed subgroup analysis on the risk of ROP ac-
cording to the age at the initiation of EPO treatment.
Preterm infants who received the initiation of EPO before
8 days of birth were classified into the early EPO group, and
infants who started EPO treatment between 8 days to
28 days of age were classified into the late EPO group.
2.5. Quality assessment of the included studies
The quality of reporting of all included RCTs was deter-
mined according to the Cochrane Collaboration Risk of Bias
instrument. We assessed the risk of bias using a domain-
based evaluation, classifying studies primarily according to
their risk of nonrandom allocation of patients in the inter-
vention arm (sequence generation) and the concealment of
this process (allocation concealment). Additionally, blind-
ing, incomplete outcome data, and intention-to-treat
analysis were assessed. Disagreements were resolved via
a discussion among the authors of the current study.
2.6. Statistical analysis
The primary outcome of interest was the risk of ROP,
including any stage reported and Stage 3. The results
were expressed as relative risks (RR) for dichotomous out-
comes with 95% confidence intervals (CI). All p-values were
two-sided, with significance set at p < 0.05. We assessed
the p-values of the c2 test to determine heterogeneity, and
I2 for inconsistency. We regarded heterogeneity as “not
important” at I2< 40%, and “considerable” at I2> 75%.17
We used a random effects model for meta-analysis if
there was significant heterogeneity (I2 > 40%), and fixed
effects for homogeneous (I2  40%). A sensitivity analysis
was performed to assess whether the methodological
quality of the trials may have affected the results of the
meta-analysis. All statistical analyses were performed using
RevMan (Cochrane Collaboration). The potential for publi-
cation bias was examined using the funnel plot method.
3. Results
We identified 166 citations in MEDLINE, PubMed, CINAHL,
and CENTRAL databases, and via manual searches of rele-
vant journals. Figure 1 demonstrates the flow diagram of
the literature search for eligible trials. Overall, 13
RCTs1e3,16,18e26 including a total of 1999 patients were
included in this analysis. Of these 1999 patients, 1051 who
received EPO were assigned into the treatment group, and
948 who received either a sham injection as a placebo or no
treatment were assigned into the control group. Details
regarding the interventions, baseline characteristics,
gestational age, birth body weight (BBW), EPO dosage and
duration, use of a placebo or not, and primary outcome of
each study are summarized in Table 1. Overall, the dosage
and duration of EPO treatment varied among the studies.
The primary outcome of most of the studies was the use of
RBC transfusion rather than the risk of ROP.1e3,18,20,23e26
None of the studies described the policies of oxygenPlease cite this article in press as: Chou H-H, et al., Early Erythropo
Preterm Infants, Pediatrics and Neonatology (2016), http://dx.doi.orgmanagement or target range of SpO2. Only two of the
studies reported the duration on mechanical ventilation
and oxygen supplementation.2,20 The risk of bias assess-
ment is described in Table 2. Blinding of the interventions
was found in eight of the 13 trials, including sham injections
in seven. The methods of randomization were not well
described in five of the trials, and allocation concealment
was unclear in three of the RCTs reviewed.
3.1. Effects on ROP of any stage
Eleven RCTs provided data regarding the incidence of ROP
of any stage in both treatment and control group-
s.1e3,16,18e24 Heterogeneity was not significant between the
estimates of ROP of any stage (c2 Z 3.67; p Z 0.98;
I2Z 0%), and the pooling of all data revealed no significant
differences in the risk of ROP between the treatment and
control groups (RR: 0.99, 95% CI: 0.84e1.16, p Z 0.89; 11
studies, 1836 infants; Figure 2). Furthermore, when all
trials were stratified into the early and late EPO subgroups,
there were no significant differences in the pooled risk ratio
of ROP for any stage in the two groups (early EPO group RR:
1.03, 95% CI: 0.86e1.23, pZ 0.78; late EPO group RR: 0.84,
95% CI: 0.60e1.16, p Z 0.29).
3.2. Effects on ROP ‡ Stage 3
Eight RCTs assessed the risk of ROP  Stage 3 in 1135
patients.2,3,18,19,21,24e26 Overall, EPO treatment did not
result in a significant increase in ROP  Stage 3 compared
with the control group (RR: 1.34, 95% CI: 0.90e1.99,
p Z 0.15; eight studies, 1134 infants; heterogeneity
c2 Z 4.85, p Z 0.85, I2 Z 0%; Figure 3). After dividing the
trials into two subgroups according to the timing of EPO
treatment, there were still no significant differences in the
risk of ROP  Stage 3 in both groups (early EPO group RR:
1.37, 95% CI: 0.87e2.17, pZ 0.18; late EPO group RR: 1.24,
95% CI: 0.56e2.78, p Z 0.60).
3.3. Sensitivity analysis and publication bias
We repeated the analysis by excluding studies that did not
blind the intervention for additional sensitivity analysis.
The risks of ROP (any stage and stage  Stage 3) were
comparable between the EPO treatment and control group
(ROP of any stage RR: 0.99, 95% CI: 0.83e1.19, p Z 0.94;
ROP  Stage 3 RR: 1.32, 95% CI: 0.88e1.97, p Z 0.18).
Because gestational age and BBW are closely related to the
maturation of retina, subgroup analysis by stratifying the
BBW of the included studies (i.e., BBW < 1000 g vs.
BBW 1000 g) was also performed to examine the associ-
ation of EPO and risk of ROP in preterm infants with
different BBW. The risks of ROP (any stage and
stage  Stage 3) were comparable between the EPO
treatment and control group (ROP of any stage RR: 0.95,
95% CI: 0.76e1.18, p Z 0.64; ROP  Stage 3 RR: 1.30, 95%
CI: 0.61e2.80, p Z 0.50). Furthermore, the substitution of
the random-effects model with the fixed model did not
change our initial qualitative interpretation of the pooled
treatment effects on all outcomes. There was no evidence
of publication bias, as the funnel plots exhibited visuallyietin Administration does not Increase the Risk of Retinopathy in
/10.1016/j.pedneo.2016.03.006
Figure 1 Flow diagram of the literature search strategy used to identify the randomized or quasi-randomized clinical trials.
CENTRALZ The Cochrane Central Register of Controlled Trials; CINAHLZ Cumulative Index to Nursing and Allied Health Literature;
RCT Z randomized controlled trial.
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Stage 3 (Figures S1 and S2).4. Discussion
In this updated meta-analysis on the role of EPO for pre-
mature infants, neither early nor late EPO administration
significantly increased the risk of either ROP of any stage or
ROP  Stage 3. This finding is different from a previous
Cochrane review4 but consistent with another recent meta-
analysis by Xu et al.27 However, our meta-analysis differs
from that by Xu et al7 in several regards. Firstly, we only
included RCTs and quasi-RCTs as in the Cochrane review,Please cite this article in press as: Chou H-H, et al., Early Erythropo
Preterm Infants, Pediatrics and Neonatology (2016), http://dx.doi.orgwhereas Xu et al7 included all controlled studies including
RCTs, cohort studies, and one case-control study in which
causal relationships may be biased by uncontrolled con-
founders. Secondly, our search was more comprehensive
than that performed by Xu et al7 as we included 13 RCTs
compared with six in the study by Xu et al.7 Thus, our meta-
analysis provides more comprehensive information
regarding the association of EPO and the risk of ROP in
preterm infants.
This updated meta-analysis provides important infor-
mation regarding the use of EPO in preterm infants, since
currently available evidence suggests that EPO treatment
significantly decreases anemia of prematurity1e3 and has a
neuroprotective effect in preterm infants with asphyxia,ietin Administration does not Increase the Risk of Retinopathy in
/10.1016/j.pedneo.2016.03.006
Table 1 Characteristics of the included studies.
Studies/y No. of
patients
Gestational
age (wk)
Birth body weight (g) Intervention Placebo Iron supplement Primary outcome
Al-Kharfy
et al,25 1996
55 EPO 26.5  1.3 EPO 929  176 EPO 200 U/kg sc TIW for
6 wk
Sham injection Oral iron 6 mg/kg/d in all
infants
Use of RBC transfusion
Control 26.4  1.5 Control 937  172
Arif and
Ferhan,1
2005
292 29.9  1.2 1096  283 EPO 200 U/kg sc BIW for
6 wk
No Oral iron 3e5 mg/kg/d
since in all infants
Use of RBC transfusion
Carnielli
et al,19 1998
63 29.6  2.1 1300  280 EPO 400 U/kg TIW, iv or
sc to 8 wk
No No* Use of RBC transfusion
Fauchere
et al,20 2008
39 28.5  2.0 1102  349 EPO 3000 U/kg iv 3e6 h,
12e18 h, and 36e42 h
after birth
Sham injection N.A. Safety, adverse effects
of early high-dose EPO
Haiden et al,21
2005
40 25.6 (23.9e31.3)y EPO 690 (500e800)y
Control 690 (467
e783)y
EPO 300 IU/kg/d iv or sc
TIW to 35 wk gestation
No EPO: iv iron 1.5 mg/kg/d þ oral
iron 9 mg/kg/dPlacebo: oral
iron 9 mg/kg/d
Plate activity, peripheral
platelet counts and
TOþ platelets
Leuchter
et al,16 2014
461 29.2  1.4 1209  344 EPO 3000 U/kg iv 3e6, 12
e18 h and 36e42 h after
birth
Sham injection N.A. Neurodevelopmental
outcome, white matter
disease
Maier et al,2
1994
241 EPO 29 (27, 30)z
Control 29 (27, 31)z
EPO 1150 (983, 1310)z
Control 1190 (1040,
1370)z
EPO 250 IU/kg sc TIW for
17 doses
No placebo but
adhesive tape on
both thighs
Oral iron 2 mg/d in all infants Use of RBC transfusion
Maier et al,18
2002
219 26 (25, 28)z EPO 778 (660, 880)z
Control 800 (700,
885)z
EPO 250 IU/kg TIW sc for
9 wk
Sham injection Oral iron 3 mg/d since Day 3e5
in all infants
Use of RBC transfusion
Ohls et al,3
2001a
172 26  2 763  135 EPO 400 IU/kg iv or sc
TIW to 35 wk gestation
Sham injection EPO: iv iron 5 mg/kg/
wkPlacebo: iv iron 1 mg/kg/wk
Use of RBC transfusion
Ohls et al,3
2001b
118 28.5  2 1124  100 EPO 400 IU/kg iv or sc
TIW to 35 wk gestation
Sham injection EPO: iv iron 5 mg/kg/
wkPlacebo: iv iron 1 mg/kg/wk
Use of RBC transfusion
Ohls et al,24
2013
62 27.7  1 .8 946  196 EPO 400 IU/kg sc TIW to
35 wk gestation
Sham injection Oral or Iv iron 3 mg/kg/wk in all
infants
Use of RBC transfusion
Pollak et al,22
2001
19 EPO 27.7  0.6 EPO 92 3  74 EPO 300 IU/kg iv at 3-d
interval for 18 d þ oral
iron supplementation
Oral iron Oral iron polymaltose complex
9 mg/kg/d in all infants*
Efficacy and safety of
iron supplementation
with EPO
Control 27.8  0.7 Control 1021  84
Shannon
et al,26 1995
157 26.9  1.6 924  183 EPO 100 IU/kg sc 5 d/wk
for 6 wk
Sham injection Oral iron 3 mg/kg/d in all
infants
Use of RBC transfusion
Yeo et al,23
2001
100 28.3  2.0 988  251 EPO 250 U/kg TIW sc Day
5e40
No oral iron 3 mg/d since Day 10 in
all infants
Use of RBC transfusion
Data are given as mean  standard deviation unless stated otherwise.
BIW Z twice per week; EPO Z erythropoietin; iv Z intravenously; RBC Z red blood cell; ROP, retinopathy of prematurity; sc Z subcutaneously; TIW Z three times per week;
TOþ Z thiazole orange-positive.
* Another group with erythropoietin plus intravenous iron treatment was not included in our meta-analysis.
y Data expressed as median and range.
z Data expressed as median and quartile range.
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Table 2 Summary of risk bias assessment.
Studies/y Adequate
sequence
generation
Allocation
concealment
Blinding of
outcome
measurement
Baseline
comparability
Incomplete
outcome data
Intention-to-treat
analysis
Al-Kharfy et al,25 1996 Unclear Yes Yes Yes No Yes
Arif and Ferhan,1 2005 Yes Unclear No Yes No Yes
Carnielli et al,19 1998 Unclear Unclear No Yes No Yes
Fauchere et al,20 2008 Yes Yes Yes Yes No Yes
Haiden et al,21 2005 Unclear Yes No Yes No Yes
Leuchter et al,16 2014 Yes Yes Yes Yes Yes* Yes
Maier et al,2 1994 Yes Yes Yes Yes Yesy Yes
Maier et al,18 2002 Yes Yes Yes Yes No Yes
Ohls et al,3 2001a Yes Yes Yes Yes No Yes
Ohls et al,3 2001b Yes Yes Yes Yes No Yes
Ohls et al,24 2013 Yes Yes Yes Yes No Yes
Pollak et al,22 2001 Unclear Yes No Yes No Yes
Shannon et al,26 1995 Yes Yes Yes Yes No Yes
Yeo et al,23 2001 Unclear Unclear No Yes No Yes
* The primary outcome of the study, neurodevelopment at 2 years, was not reported.
y Three infants who underwent randomization were excluded (data were lost on 2 infants, and treatment was inadvertently omitted in
1 infant).
Figure 2 The effects of erythropoietin (EPO) treatment versus a placebo or no treatment on the rate of retinopathy of pre-
maturity of any stage reported. CI Z confidence interval.
6 H.-H. Chou et al
+ MODELintraventricular hemorrhage, or periventricular
leukomalacia.15,16
The effect of EPO on ROP in preterm infants has been
debated for long time. Previous Cochrane reviews have
shown that the early administration of EPO significantly
increases the rate of severe ROP (Stage 3),28 whereas the
late administration of EPO does not.29 A recent updated
meta-analysis revealed that early EPO does not significantlyPlease cite this article in press as: Chou H-H, et al., Early Erythropo
Preterm Infants, Pediatrics and Neonatology (2016), http://dx.doi.orgincrease the rate of ROP (Stage 3), although post hoc
analysis including all studies that reported on ROP Stage 3
regardless of age of initiation of EPO concluded that there
was an increased risk of ROP.4 Our meta-analysis differs
from the Cochrane review in several aspects. Firstly, our
meta-analysis enrolled more updated RCTs regarding the
risk of EPO on ROP in preterm infants, and thus provides
more comprehensive information, including one multi-ietin Administration does not Increase the Risk of Retinopathy in
/10.1016/j.pedneo.2016.03.006
Figure 3 The effects of erythropoietin (EPO) treatment versus a placebo or no treatment on the rate of retinopathy of pre-
maturity of Stage 3. Unpublished data from the study by Maier et al18 (2002) was obtained from a previous Cochrane review.
CI Z confidence interval.
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+ MODELcenter RCT that tested high dose EPO in premature in-
fants16 which was not included in the previous Cochrane
review. Secondly, one study that reported that the inci-
dence of ROP was significantly higher in preterm infants
receiving both EPO and iron supplementation was excluded
in our meta-analysis.30 In addition to EPO treatment, iron
supplementation was given intravenously in the treatment
group but not the control group, and iron supplementation
may confound the association of EPO treatment and the risk
of ROP.30 The authors also found a significant positive cor-
relation between the incidence and the severity of ROP and
serum ferritin concentration during various stages of
treatment, which suggests that iron supplementation may
play an important role in the risk of ROP. Furthermore, the
incidence of chronic lung disease at 28 days was higher in
the treatment group than in the control group (pZ 0.0465)
in their study, implying that the treatment group may have
needed a higher concentration of oxygen therapy, which
could also contribute to the development of ROP. This study
was therefore removed from our meta-analysis, and the
results proved our hypothesis that there was no difference
in either the incidence or severity of ROP between the EPO
and control groups after removing the study. There was no
heterogeneity in relative risk of the pooled results in the
current study (I2 Z 0%), and there did not seem to be any
evidence of possible publication bias in the outcomes as the
funnel plots were symmetrical.
Excessive levels of iron are toxic to tissues due to the
Fenton reaction, and the production of hydroxyl radicals
can cause oxidative damage to lipids, proteins, and DNA.31
The association between iron supplementation and risk of
ROP was evaluated in a few studies. Inder et al32 reported
that an elevated serum iron level and transferrin saturation
at 7 days of age appeared to be associated with an
increased risk of ROP. In addition, a prospectivePlease cite this article in press as: Chou H-H, et al., Early Erythropo
Preterm Infants, Pediatrics and Neonatology (2016), http://dx.doi.orgobservational study demonstrated that gestational age,
transfusion volume, and iron intake were associated with
the development of ROP.33 The authors speculated that this
risk was related to the ability of iron to cause oxidative
injury of the retinal vessels. Furthermore, Hirano et al34
reported that iron overload rather than the number of
transfusions may contribute to the development of ROP.
EPO has been shown to regulate angiogenesis in
humans.35 Sato et al36 found that both EPO and vascular
endothelial growth factor were significantly increased in
the vitreous of infants with vascularly active ROP, whereas
this was not seen in the vitreous of eyes without ROP. Chen
and Smith37 suggested that EPO may act as a so-called
double-edged sword in eyes with ROP. The angiogenic ac-
tion of EPO may be crucial in the first phase of ROP, which
can occur up to a postmenstrual age of 30 weeks, when its
concentration in the eye can prevent vascular apoptosis
and stimulate angiogenesis, whereas in the second phase its
angiogenic effect may increase abnormal neo-
vascularization leading to a worsening of ROP. According to
this hypothesis and with the aim of preventing ROP, EPO
may induce angiogenesis and inhibit apoptosis of retinal
vasculature in the first phase; however, as proliferative ROP
begins, EPO may cause hypoxia and ischemia.38
Some studies showed that the frequency of blood
transfusion is an independent risk factor for the develop-
ment of ROP.39,40 This may be partly explained by trans-
fused adult RBCs being rich in 2,3-diphospoglycerate and
that they bind less firmly to oxygen, thus releasing excess
oxygen to the retinal tissue of premature infants. Given the
beneficial effects of EPO on reducing the frequency of RBC
transfusions, preterm infants who receive EPO treatment
should require fewer RBC transfusions and less iron loading,
which should then result in a lower risk of ROP. Thus, the
amount of blood transfusion maybe a potential confoundingietin Administration does not Increase the Risk of Retinopathy in
/10.1016/j.pedneo.2016.03.006
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studies3,22 in the included studies that reported the amount
of RBC transfusion was not significantly different between
the EPO group and placebo group. If we pooled the data of
these studies together, the risks of ROP (any stage and
stage  Stage 3) were still comparable between the EPO
treatment and control group (ROP of any stage RR: 1.23,
95% CI: 0.71e2.13; ROP  Stage 3 RR: 1.29, 95% CI:
0.71e2.34). This also supports that EPO administration
should not increase the risk of ROP in preterm infants;
however, further studies are needed to clarify the role of
blood transfusion and iron load in the risk of ROP.
The main limitation of our study is related to the quality
of the available RCTs. Previous RCTs regarding the admin-
istration of EPO in preterm infants mostly aimed to inves-
tigate whether EPO administration could reduce the
frequency and volume of blood transfusion. Confounding
factors also existed, as most of the studies were not
designed primarily to investigate the association of EPO
treatment and the incidence of ROP. Risk factors for ROP
such as hyperoxia, hypoxia, hypotension, acidosis, duration
of ventilation, sepsis, apnea, and postnatal steroid treat-
ment were not reported in most of the studies. Further-
more, the gestational age, birth weight of the preterm
infants, and the dosage and duration of EPO varied in the
included studies.
In conclusion, our meta-analysis demonstrated that EPO
therapy, regardless of the age at initiation of treatment,
does not significantly increase the incidence or severity of
ROP in preterm infants. Further randomized controlled
trials to investigate the impact of EPO on ROP in premature
infants should include all related confounding factors with
a large sample size.
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